Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run

investors.com/news/technology/anaptysbio-stock-ulcerative-colitis-treatment-failure

AnaptysBio stock plummeted Monday, reversing a recent run, after its experimental ulcerative colitis drug failed in midstage testing.
The post Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-11-10 16:22:07.
The Entire Business World on a Single Page. Free to Use →